Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Operating Leases (2019 - 2021)

Historic Operating Leases for Cyclerion Therapeutics (CYCN) over the last 3 years, with Q1 2021 value amounting to $38.1 million.

  • Cyclerion Therapeutics' Operating Leases fell 1910.11% to $38.1 million in Q1 2021 from the same period last year, while for Mar 2021 it was $38.1 million, marking a year-over-year decrease of 1910.11%. This contributed to the annual value of $38.9 million for FY2020, which is 4477.59% down from last year.
  • Per Cyclerion Therapeutics' latest filing, its Operating Leases stood at $38.1 million for Q1 2021, which was down 1910.11% from $38.9 million recorded in Q4 2020.
  • In the past 5 years, Cyclerion Therapeutics' Operating Leases registered a high of $72.4 million during Q2 2019, and its lowest value of $38.1 million during Q1 2021.
  • Its 3-year average for Operating Leases is $53.1 million, with a median of $46.7 million in 2020.
  • Per our database at Business Quant, Cyclerion Therapeutics' Operating Leases plummeted by 4477.59% in 2020 and then crashed by 1910.11% in 2021.
  • Over the past 3 years, Cyclerion Therapeutics' Operating Leases (Quarter) stood at $70.5 million in 2019, then plummeted by 44.78% to $38.9 million in 2020, then decreased by 2.22% to $38.1 million in 2021.
  • Its Operating Leases stands at $38.1 million for Q1 2021, versus $38.9 million for Q4 2020 and $39.8 million for Q3 2020.